Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 525

1.

Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.

Yaghi S, Kamel H, Elkind MS.

Neurology. 2015 Jul 17. pii: 10.1212/WNL.0000000000001817. [Epub ahead of print] Review.

PMID:
26187229
2.
3.

Protocol for Cerebral Microbleeds During the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients With Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial.

Takizawa S, Tanaka F, Nishiyama K, Hasegawa Y, Nagata E, Mizuma A, Yutani S, Nakayama T, Kobayashi H, Yanagimachi N, Okazaki T, Kitagawa K; CMB-NOW Study Investigators.

J Stroke Cerebrovasc Dis. 2015 Jul 4. pii: S1052-3057(15)00315-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.05.032. [Epub ahead of print]

PMID:
26153510
4.

Trends and Characteristics of Emergency Department Patients Prescribed Novel Oral Anticoagulants.

Ganetsky M.

J Emerg Med. 2015 Jul 3. pii: S0736-4679(15)00375-3. doi: 10.1016/j.jemermed.2015.04.028. [Epub ahead of print]

PMID:
26149803
5.

Spontaneous Hemopericardium in a Patient Receiving Apixaban Therapy: First Case Report.

Sigawy C, Apter S, Vine J, Grossman E.

Pharmacotherapy. 2015 Jul;35(7):e115-7. doi: 10.1002/phar.1602. Epub 2015 Jun 10.

PMID:
26095120
6.

Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry.

Chishaki A, Kumagai N, Takahashi N, Saikawa T, Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Sakurai M, Kawamura Y, Kubota I, Matsumoto K, Kaneko Y, Ogawa S, Aizawa Y, Chinushi M, Kodama I, Watanabe E, Koretsune Y, Okuyama Y, Shimizu A, Igawa O, Bando S, Fukatani M; J-RHYTHM Registry Investigators.

Thromb Res. 2015 Jun 11. pii: S0049-3848(15)30021-9. doi: 10.1016/j.thromres.2015.06.009. [Epub ahead of print]

PMID:
26092429
7.

Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Blann AD, Skjøth F, Rasmussen LH, Larsen TB, Lip GY.

Thromb Haemost. 2015 Jul 28;114(2):403-9. doi: 10.1160/TH15-05-0383. Epub 2015 Jun 11.

PMID:
26062437
8.

NON-VITAMIN ORAL ANTICOAGULANTS (NOACs) A review of clinical management and laboratory issues.

Blann A.

Curr Vasc Pharmacol. 2015 Jun 9. [Epub ahead of print]

PMID:
26059459
10.

Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution.

Tagaya M, Yoshikawa D, Sugishita Y, Yamauchi F, Ito T, Kamada T, Yoshinaga M, Mukaide D, Fujiwara W, Yokoi H, Hayashi M, Watanabe E, Ishii J, Ozaki Y, Izawa H.

Heart Vessels. 2015 May 29. [Epub ahead of print]

PMID:
26022376
11.

Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis.

Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Crowther M.

Thromb Haemost. 2015 May 28;114(4). [Epub ahead of print]

PMID:
26018236
12.

Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda.

Chen CH, Chen MC, Gibbs H, Kwon SU, Lo S, On YK, Rosman A, Suwanwela NC, Tan RS, Tirador LS, Zirlik A.

Int J Cardiol. 2015 Jul 15;191:244-253. doi: 10.1016/j.ijcard.2015.03.369. Epub 2015 Mar 27. Review.

PMID:
25978611
13.
14.

Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin.

Kim E, Ozonoff A, Hylek EM, Berlowitz DR, Ash AS, Miller DR, Zhao S, Reisman JI, Jasuja GK, Rose AJ.

Thromb Haemost. 2015 Jun 30;114(1):70-7. doi: 10.1160/TH14-09-0754. Epub 2015 May 7.

PMID:
25948532
15.

The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.

Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K.

Pathology. 2015 Jun;47(4):355-64. doi: 10.1097/PAT.0000000000000252.

PMID:
25938348
16.

Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial Fibrillation.

Steinberg BA, Greiner MA, Hammill BG, Curtis LH, Benjamin EJ, Heckbert SR, Piccini JP.

Cardiovasc Ther. 2015 Aug;33(4):177-83. doi: 10.1111/1755-5922.12129.

PMID:
25930214
17.

Safety of new oral anticoagulants.

Vaughan Sarrazin MS, Rose A.

BMJ. 2015 Apr 24;350:h1679. doi: 10.1136/bmj.h1679. No abstract available.

PMID:
25911527
18.

Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.

Chang HY, Zhou M, Tang W, Alexander GC, Singh S.

BMJ. 2015 Apr 24;350:h1585. doi: 10.1136/bmj.h1585.

19.

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.

BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.

20.

Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis.

Rong F, Jia B, Huang P, Lynn HS, Zhang W.

Thromb Res. 2015 Jun;135(6):1117-23. doi: 10.1016/j.thromres.2015.04.004. Epub 2015 Apr 11.

PMID:
25891842
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk